ACUMEN PHARMACEUTICALS INC (ABOS) Fundamental Analysis & Valuation

NASDAQ:ABOS • US00509G2093

Current stock price

2.835 USD
+0.1 (+3.85%)
Last:

This ABOS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ABOS Profitability Analysis

1.1 Basic Checks

  • ABOS had negative earnings in the past year.
  • ABOS had a negative operating cash flow in the past year.
  • In the past 5 years ABOS always reported negative net income.
  • ABOS had a negative operating cash flow in each of the past 5 years.
ABOS Yearly Net Income VS EBIT VS OCF VS FCFABOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • ABOS has a Return On Assets of -98.78%. This is in the lower half of the industry: ABOS underperforms 75.78% of its industry peers.
  • The Return On Equity of ABOS (-172.28%) is worse than 67.64% of its industry peers.
Industry RankSector Rank
ROA -98.78%
ROE -172.28%
ROIC N/A
ROA(3y)-27.12%
ROA(5y)-28.31%
ROE(3y)-32.81%
ROE(5y)-32.47%
ROIC(3y)N/A
ROIC(5y)N/A
ABOS Yearly ROA, ROE, ROICABOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • ABOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABOS Yearly Profit, Operating, Gross MarginsABOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ABOS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ABOS has been increased compared to 1 year ago.
  • ABOS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ABOS is higher compared to a year ago.
ABOS Yearly Shares OutstandingABOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
ABOS Yearly Total Debt VS Total AssetsABOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • ABOS has an Altman-Z score of -5.26. This is a bad value and indicates that ABOS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of ABOS (-5.26) is worse than 65.12% of its industry peers.
  • A Debt/Equity ratio of 0.32 indicates that ABOS is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.32, ABOS is not doing good in the industry: 68.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -5.26
ROIC/WACCN/A
WACCN/A
ABOS Yearly LT Debt VS Equity VS FCFABOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 4.07 indicates that ABOS has no problem at all paying its short term obligations.
  • ABOS has a Current ratio (4.07) which is comparable to the rest of the industry.
  • ABOS has a Quick Ratio of 4.07. This indicates that ABOS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.07, ABOS is in line with its industry, outperforming 50.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.07
Quick Ratio 4.07
ABOS Yearly Current Assets VS Current LiabilitesABOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ABOS Growth Analysis

3.1 Past

  • ABOS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.54%.
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 12.75% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.77%
EPS Next 2Y17.92%
EPS Next 3Y17.52%
EPS Next 5Y12.75%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABOS Yearly Revenue VS EstimatesABOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2028 2031 2032 2033 20M 40M 60M 80M 100M
ABOS Yearly EPS VS EstimatesABOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. ABOS Valuation Analysis

4.1 Price/Earnings Ratio

  • ABOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABOS Price Earnings VS Forward Price EarningsABOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABOS Per share dataABOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ABOS's earnings are expected to grow with 17.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y17.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABOS Dividend Analysis

5.1 Amount

  • No dividends for ABOS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABOS Fundamentals: All Metrics, Ratios and Statistics

ACUMEN PHARMACEUTICALS INC

NASDAQ:ABOS (4/22/2026, 3:00:04 PM)

2.835

+0.1 (+3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26
Earnings (Next)05-11
Inst Owners61.5%
Inst Owner Change0.89%
Ins Owners2.31%
Ins Owner Change11.99%
Market Cap204.72M
Revenue(TTM)N/A
Net Income(TTM)-121.33M
Analysts88.33
Price Target7.34 (158.91%)
Short Float %1.57%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.92%
Min EPS beat(2)11.3%
Max EPS beat(2)28.53%
EPS beat(4)3
Avg EPS beat(4)11.24%
Min EPS beat(4)-23.92%
Max EPS beat(4)29.06%
EPS beat(8)4
Avg EPS beat(8)-3.66%
EPS beat(12)7
Avg EPS beat(12)1.5%
EPS beat(16)7
Avg EPS beat(16)-3.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.86%
PT rev (3m)12.5%
EPS NQ rev (1m)-5.99%
EPS NQ rev (3m)-5.99%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.91
P/tB 2.91
EV/EBITDA N/A
EPS(TTM)-2.01
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS0.98
TBVpS0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -98.78%
ROE -172.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.12%
ROA(5y)-28.31%
ROE(3y)-32.81%
ROE(5y)-32.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.07
Quick Ratio 4.07
Altman-Z -5.26
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)197.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.87%
EPS Next Y27.77%
EPS Next 2Y17.92%
EPS Next 3Y17.52%
EPS Next 5Y12.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.58%
EBIT Next 3Y653.25%
EBIT Next 5Y-8.92%
FCF growth 1Y-100.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-100.2%
OCF growth 3YN/A
OCF growth 5YN/A

ACUMEN PHARMACEUTICALS INC / ABOS Fundamental Analysis FAQ

What is the fundamental rating for ABOS stock?

ChartMill assigns a fundamental rating of 1 / 10 to ABOS.


What is the valuation status of ACUMEN PHARMACEUTICALS INC (ABOS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ACUMEN PHARMACEUTICALS INC (ABOS). This can be considered as Overvalued.


How profitable is ACUMEN PHARMACEUTICALS INC (ABOS) stock?

ACUMEN PHARMACEUTICALS INC (ABOS) has a profitability rating of 0 / 10.


What is the financial health of ACUMEN PHARMACEUTICALS INC (ABOS) stock?

The financial health rating of ACUMEN PHARMACEUTICALS INC (ABOS) is 3 / 10.